Vitreous -Retina- Macula Consultants of New York (VRMNY)   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: New York NY United States (1974)

Organization Overview

First Clinical Trial
2006
NCT00403325
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Vitreous -Retina- Macula Consultants of New York | Vitreous Retina Macula Consultants of New York, P.C.

Active Ingredients

Drugs in Phase 4 Trials (1)

aflibercept (zaltrap) (4 trials)

Drugs in Phase 2 Trials (1)

ranibizumab (lucentis) (5 trials)

Drugs in Phase 1 Trials (3)

efalizumab (Raptiva) (1 trial)

imatinib (gleevec) (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Other Trials (2)

urea (1 trial)

verteporfin (visudyne) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Central Serous Chorioretinopathy (Phase 1)

Choroidal Neovascularization (Phase 1)

Macular Degeneration (Phase 2)

Macular Edema (Phase 1)

Neovascularization, Pathologic (Phase 1)

Retinal Detachment (Phase 4)

Retinal Vein Occlusion (Phase 1)

Wet Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 7